Survival benefit of boron neutron capture therapy for recurrent malignant gliomas

Shin Ichi Miyatake, Shinji Kawabata, Kunio Yokoyama, Toshihiko Kuroiwa, Hiroyuki Michiue, Yoshinori Sakurai, Hiroaki Kumada, Minoru Suzuki, Akira Maruhashi, Mitsunori Kirihata, Koji Onoc

    Research output: Contribution to journalArticlepeer-review

    13 Citations (Scopus)


    We have applied boron neutron capture therapy (BNCT) to malignant brain tumors. Here we evaluated the survival benefit of BNCT for recurrent malignant glioma (MG). Since 2002, we have treated 22 cases of recurrent MG with BNCT. Survival time was analyzed with special reference to recursive partitioning analysis (RPA) classification, by Carson et al. Median survival times (MSTs) after BNCT for all patients and for glioblastoma as on-study histology at recurrence was 10.8 months (n=22; 95% CI, 7.3-12.8 months) and 9.6 months (n=19; 95% CI, 6.9-11.4 months), respectively. In our study, MST for the high-risk RPA classes was 9.1 months (n=11; 95% CI, 4.4-11.0 months). By contrast, the original journal data showed that the MST of the same RPA classes was 4.4 months (n=129; 95% CI, 3.6-5.4 months). BNCT showed a survival benefit for recurrent MG, especially in the high-risk group.

    Original languageEnglish
    Pages (from-to)S22-S24
    JournalApplied Radiation and Isotopes
    Issue number7-8 SUPPL.
    Publication statusPublished - Jul 2009


    • Boronophenylalanine PET
    • Glioblastoma
    • Malignant glioma
    • Recursive partitioning analysis (RPA)

    ASJC Scopus subject areas

    • Radiation


    Dive into the research topics of 'Survival benefit of boron neutron capture therapy for recurrent malignant gliomas'. Together they form a unique fingerprint.

    Cite this